

Revusiran

Cat. No.:	HY-132590
CAS No.:	1438322-82-7
Target:	Transthyretin (TTR); Small Interfering RNA (siRNA)
Pathway:	Neuronal Signaling; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Revusiran

BIOLOGICAL ACTIVITY

Description	Revusiran (ALN-TTRSC) is a 1st-generation short interfering RNA, which directed against transthyretin (TTR) mRNA. Revusiran can be used for transthyretin (TTR)-mediated amyloidosis research ^[1] .
In Vitro	Revusiran is a chemically synthesized double-stranded siRNA that is covalently linked at the 3'-end of its sense strand to a ligand containing three GalNAc residues. Revusiran is a 1st-generation short interfering RNA targeting transthyretin conjugated to an N-acetylgalactosamine ligand to facilitate delivery to hepatocytes via uptake by the asialoglycoprotein receptors ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	There are no effects on cardiovascular or respiratory function in monkeys after single doses of up to 100 mg/kg. No neurological effects were noted in monkeys in repeat-dose studies up to 300 mg/kg. Revusiran is well tolerated in repeat-dose mouse (weekly doses) and rat and monkey (five daily doses followed by weekly doses) toxicity studies ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Jessica E Sutherland, et al. Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis. *Nucleic Acid Ther.* 2020 Feb;30(1):33-49.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA